share_log

盟科药业(688373.SH):注射用MRX-4序贯康替唑胺片用于耐药革兰氏阳性菌感染适应症获得临床试验批准通知书

Mengke Pharmaceutical (688373.SH): Injectable MRX-4 sequential contizolamide tablets for drug resistant gram-positive bacteria infection indications obtained a clinical trial approval notice

Gelonghui Finance ·  Nov 23, 2023 04:00

Gelonghui November 23丨Mengke Pharmaceutical (688373.SH) announced that it has recently received the “Drug Clinical Trial Approval Notice” approved and issued by China's State Drug Administration on contizolamide tablets and injectable MRX-4 for treatment of drug-resistant gram-positive bacterial infections. Contizolid tablets and MRX-4 for injection are innovative oxazolidinone antimicrobial drugs independently developed by the company and have global intellectual property rights.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment